| Description |
COX-2-IN-24 is an orally active inhibitor of COX-2 with IC50 value of 0.17 μM, shows anti-inflammatory and low ulcerogenic activities.
|
| Related Catalog |
|
| Target |
COX-2:0.17 μM (IC50)
|
| In Vivo |
COX-2-IN-24 (Intraperitoneal injection; 9mg/100g; once an hour; 4 hours) shows anti-inflammatory activity in the carrageenan-induced rat paw edema model[1]. COX-2-IN-24 (Oral gavage; 9mg/100g; once a day; 3 days) shows low ulcerogenic activity in the received 1% gum acacia (suspending vehicle) orally male albino rats model [1]. Animal Model: Mature male albino rats[1] Dosage: 9mg/100g Administration: Intraperitoneal injection; 9mg/100g; once an hour; 4 hours Result: Exhibited a promising anti-inflammatory activity in the carrageenan-induced rat paw edema model. Animal Model: Mature male albino rats[1] Dosage: 9mg/100g Administration: Oral gavage; 9mg/100g; once a day; 3 days Result: Exhibited low ulcerogenic activity in the received 1% gum acacia (suspending vehicle) orally male albino rats model.
|
| References |
[1]. Tarek S Ibrahim, et al. Design, synthesis, and pharmacological evaluation of novel and selective COX-2 inhibitors based on bumetanide scaffold. Bioorg Chem. 2020 Jul;100:103878.
|
